Combining Corticosteroid With Standard Treatment can Help Improve Eyesight in NAION Patients

by Kathy Jones on November 22, 2013 at 9:10 PM

A new study published in the journal Restorative Neurology and Neuroscience suggests that combining corticosteroid fluocortolone (FC) with standard therapy can lead to a significant improvement in both short- and long-term visual acuity, especially when given soon after the onset of symptoms, in patients with nonarteritic anterior ischemic optic neuropathy (NAION).

NAION, a disabling condition which can affect both eyes in up to 19% of cases within 5 years, occurs in about 2.3 per 100,000 adults over the age of 50. Incidence increases steadily with age. Patients have few well-tested or effective treatment options beyond the standard administration of pentoxifylline (PTX), which is thought to improve visual acuity by improving the microcirculation in oxygen-deprived optic nerve tissue. No current treatment reverses or limits the course of the disease. The goal of the current study was to see whether adding a steroid to PTX could improve vision, perhaps by reducing edema or inflammation.

Amblyopia

Amblyopia is the loss of one eye''s ability to see details. Amblyopia is otherwise known as lazy eye.

Researchers from the Institute of Experimental Ophthalmology, University of Münster, Germany, studied 55 patients diagnosed with NAION who had developed sudden loss of visual acuity less than 3 days before the initial consultation. These patients were treated with PFX as well as adjunctive therapy with FC during the first 2-3 months (which was gradually tapered). The control group received only PFX.

Investigators found that PFX alone had no significant beneficial effects on either visual acuity (as measured as Best Corrected Visual Acuity, BCVA) or visual field after 3 days and 6 months of treatment. However, adding FC significantly boosted outcomes: those receiving FC were more likely to experience improvement and less likely to have worsened visual acuity. Progress was even more pronounced after 6 months of therapy. More than two thirds of NAION patients treated with the combination therapy had better long-term vision compared to only 14% of those only treated with PFX.

Allergy Eye Drops

Eye allergies are treated with different types of eye drops such as lubricants, antihistamines, NSAIDs and corticosteroids. Eye drops are used to reduce allergies, eye infection and help healing.

The authors explain why FC apparently benefits those who have less severe visual loss. "NAION is caused by ischemia of the optic nerve head.... This restriction of blood supply, depending upon its degree, results in primary irreversible loss of retinal ganglion cells (RGC) and secondary delayed RGC loss related to subsequent optic-disc edema," says Verena Prokosch, PhD, Dr. med., Institute of Experimental Ophthalmology.

"Corticosteroids do not appear to reduce primary cell death, explaining the lack of benefit of FC therapy in patients with a BCVA score worse than 0.05. This may not be the case for patients with moderate BCVA loss who suffer secondary RGC loss due to optic-nerve swelling, revealing a possible therapeutic window for FC," explains co-author Solon Thanos, MD, Prof. Dr. med. Dr. rer.nat., Institute of Experimental Ophthalmology. Prof. Dr. Thanos suggests that the pronounced long-term effect of FC on visual acuity found in the study could be attributed to early and prolonged treatment at a dose higher than previously tested.

Source: Eurekalert

Conjunctivitis

Conjunctivitis or Pink Eye causes redness and soreness of the conjunctiva and is responsible for 1% of all emergency visits to a hospital.

<< Early Start Key for a Radiant Look for Brides-To-Be

Experimental Treatment can Slow Down Prostate Cancer Spread >>

Clear the Blur-Tips to Boost Your Eye-Q

Eye problems may present as blurry vision or simply a minor headache, but they can affect your life in more ways than one. Here's a comprehensive yet compact guide to boost your eye-Q.